Conversion of the carbamazepine metabolite, 3-hydroxycarbamazepine (3-OHCBZ), to the catechol, 2,3-dihydroxycarbamazepine (2,3-diOHCBZ), followed by subsequent oxidation to a reactive o-quinone species has been proposed as a possible bioactivation pathway in the pathogenesis of carbamazepine- 
Introduction
Introduced in the early 1960's, the tricyclic compound, carbamazepine (CBZ; Tegretol), has proven to be a highly effective agent for the treatment of epileptic seizures, trigeminal neuralgia and psychiatric disorders. However, its therapeutic use has also been associated with a variety of serious idiosyncratic adverse reactions, including skin rashes, aplastic anemia, hepatitis and a severe, generalized druginduced hypersensitivity reaction, which has been estimated to occur in 1 of 5000 patients (Shear and Spielberg, 1988; Tennis and Stern, 1997) . Among patients experiencing CBZ-induced hypersensitivity reactions, significant cross-sensitivity has been reported with other aromatic anticonvulsants, such as phenytoin and phenobarbital (Shear and Spielberg, 1988) , which suggests that the mechanisms of these adverse reactions may be related. The mechanism underlying anticonvulsant-induced hypersensitivity is not well understood, but it is generally believed that biotransformation of aromatic anticonvulsants into chemically reactive metabolites is the critical event that initiates downstream pathogenic events such as formation of protein adducts and subsequent immune responses (Park et al., 1987) . Serum antibodies that recognize cytochrome P450 (P450)-related antigens; specifically epitopes present in rat CYP2C and 3A enzymes (Leeder et al., 1996) have been found in patients who have experienced a hypersensitivity reaction to aromatic anticonvulsants. Interestingly, these antibodies do not appear to recognize recombinant human CYP2C and 3A proteins; however, sera from two patients who had experienced anticonvulsant hypersensitivity reactions demonstrated pronounced immunoreactivity with an unidentified, 53 kDa protein present in liver microsomes from a patient who died of phenytoin-induced hepatitis.
Although the identity of the antigen to which the immune response is directed has remained elusive, bioactivation of CBZ has been demonstrated in vitro by the formation of both cytotoxic (Pirmohamed et al., 1993) and protein-reactive metabolites (Pirmohamed et al., 1992; Lillibridge et al., 1996; Wolkenstein et al., 1998) in human liver microsomes. Using [ DMD #19562 CYP 2C8, 2C9 or 3A4 activities in human liver microsomes preincubated with CBZ. Recently, Kang et al. (2008) demonstrated that CYP3A4 converted [ 3 H]-CBZ into a metabolite capable of covalently binding to CYP3A4, presumably within the active site. However, the CBZ-modified enzyme retained its testosterone 6β-hydroxylase activity. Unfortunately, these studies were not able to reveal the identity(s) of the proteinreactive metabolite(s).
Several reactive metabolites have been proposed as the reactive species responsible for the idiosyncratic toxicity associated with CBZ, including an arene oxide (Spielberg et al., 1981) , 9-acridine carboxaldehyde (Furst et al., 1995) , CBZ 10,11-epoxide (Bu et al., 2005) , an iminoquinone metabolite (CBZ-IQ) derived from 2-hydroxycarbamazepine (2-OHCBZ) (Ju and Utrecht, 1999) and an o-quinone metabolite (CBZquinone) (Lillibridge et al., 1996) , which is proposed to form via oxidation of the catechol, 2,3-dihydroxycarbamazepine (2,3-diOHCBZ) (Fig.1) . The latter two proposed species (CBZ-IQ and the o-quinone metabolite) are particularly attractive candidates for the reactive intermediate, since quinones are relatively soft electrophiles that react readily with soft nucleophiles and have been implicated in the production of CBZ-derived protein adducts (Pirmohamed et al., 1992; Lillibridge et al., 1996) . We recently identified CYP3A4 as the primary catalyst responsible for converting 2-OHCBZ to CBZ-IQ and observed formation of glutathione-and N-acetylcysteine-conjugates when 2-hydroxyiminostilbene (2-OHIS) or CBZ-IQ were used as substrates, but failed to observe time-dependent loss of CYP3A activity with 2-OHCBZ, 2-OHIS or CBZ-IQ (Pearce et al., 2005) . In the present study, we examined the role that human P450 enzymes play in the biotransformation of 3-OHCBZ to the catechol, 2,3-diOHCBZ, the proposed precursor to CBZ-quinone. During the course of the investigation, it was determined that CYP3A4 made a substantial contribution to 2,3-OHCBZ formation and that recombinant CYP3A4-mediated catechol formation was not proportional to time, which suggested that CYP3A4 might be inactivated by a metabolite generated from 3-OHCBZ. Hence, additional studies were undertaken to determine whether 3-OHCBZ biotransformation led to time-and concentration-dependent loss of CYP3A activity and formation of microsomal protein adducts.
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Materials and Methods
Chemicals. CBZ, α-naphthoflavone, ketoconazole, omeprazole, quinidine, sulfaphenazole, testosterone, 6β-hydroxytestosterone, TAO, GSH, glucose-6-phospate, glucose-6-phosphate dehydrogenase, isocitrate, isocitrate dehydrogenase, NAC, NADP, NADPH, and EDTA were purchased from Sigma Chemical Co. (St. Louis, MO). All other reagents were of analytical grade. Bicinchoninic acid (BCA) protein determination kits were purchased from Pierce, Inc. (Rockford, Ill). Syntheses of 3-OHCBZ and 3-hydroxy[carbonyl- 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, 3A5, and 3A7) or control vector were purchased from BD GENTEST Corp. All recombinant enzymes were co-expressed with human NADPH-cytochrome P450 reductase; some enzymes (CYP2B6, CYP2C19, CYP2E1, CYP3A4 and CYP3A7) were also coexpressed with human cytochrome b 5 . The manufacturers provided protein concentrations, P450 contents and P450 enzyme activities. Microsomes from dexamethasone (Dex)-treated mice were prepared by differential ultracentrifugation of homogenates from 1.15 M KCl-perfused livers (Bornheim and Correia, 1990) , and stored as pellets overlaid with PBS/10% glycerol at -80°C until use. Vials of microsomes were stored at -70ºC until use. Typically, microsomes were rapidly thawed in room temperature water and placed on ice prior to use. However, in protein binding experiments, microsomes were allowed to thaw on ice prior to use.
In vitro incubations with 3-OHCBZ. In vitro enzyme assays were performed in 96-well microtiter plates.
Standard incubation reactions (100-µl) contained human liver microsomes (50 µg of microsomal protein) or insect cell microsomes containing bacculovirus-expressed cytochrome P450 enzymes (5 pmol) coexpressed with P450 reductase, potassium phosphate buffer (50 mM, pH 7.4), MgCl 2 (3 mM), EDTA (1 This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on May 7, 2008 as DOI: 10.1124 at ASPET Journals on March 31, 2017 dmd.aspetjournals.org Downloaded from DMD #19562 mM), and 3-OHCBZ (5 to 500 µM) dissolved in methanol (≤ 1% v/v final concentration) at the final concentrations listed. Reactions were initiated by the addition of an NADPH-generating system, consisting of NADP (1 mM), glucose-6-phosphate (5 mM), and glucose-6-phosphate dehydrogenase (1 U/ml), incubated at 37±0.1°C in a Thermo Forma (Marietta, OH) Benchtop Orbital Shaker, and terminated after 0-60 min (standard conditions: human liver microsomes, 30 min; recombinant P450s, 60 min for screen; CYP3A4 and CYP2C19 kinetics, 10 and 15 min, respectively) by the addition of 100 µl of ice-cold methanol containing the internal standard, CBZ (1 µM final concentration). Protein was precipitated by centrifugation at 10,000 g max for 10 min. An aliquot (50-75 µl) of the supernatant was analyzed by HPLC/MS via direct injection. Under these conditions, initial experiments conducted with 3-OHCBZ (50 µM) and pooled human liver microsomes suggested that the rates of formation for the metabolite identified as 2,3-diOHCBZ were proportional to protein concentration (up to 0.5 mg/ml) and incubation time (up to 60 min). Additional experiments conducted with 3-OHCBZ at a substrate concentration of 5 µM (to establish experimental conditions for kinetic studies) demonstrated that the rate of 2,3-diOHCBZ formation was proportional to protein concentration and incubation time in pooled human liver microsomes (up to 0.5 mg/ml; up to 30 min) and microsomes containing recombinant CYP3A4 and CYP2C19 (up to 5 pmol P450; up to 10 and 15 min, respectively). With the exception of experiments designed to examine preincubation-dependent inhibition of CYP3A4/5 activity and protein binding, biotransformation of 3-OHCBZ did not exceed 10% in in vitro incubations.
Inhibition experiments. Conversion of 3-OHCBZ (100 µM) to 2,3-diOHCBZ by human liver microsomes was evaluated in the presence or absence (i.e., control) of known P450 isoform-selective inhibitors. The following chemical inhibitors were examined at the indicated concentrations: α-naphthoflavone (CYP1A2, 1 µM), sulfaphenazole (CYP2C9, 10 µM), omeprazole (CYP2C19, 10 µM), quinidine (CYP2D6, 1 µM), ketoconazole (CYP3A4/5, 1 µM) and TAO (CYP3A4/5, 100 µM). Inhibitors were dissolved in methanol and diluted in the incubation mixtures to a final solvent concentration of 1% (v/v). Control incubations contained an equal volume of methanol. Incubations containing the mechanism-based inhibitor troleandomycin were pre-incubated with human liver microsomes and NADPH-generating system for 20 min before the reaction was started with substrate.
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Preincubation-dependent inhibition of CYP3A4/5 activity. Human liver microsomes (0.5 mg protein/ml) and recombinant CYP3A4 (50 pmol/ml) were preincubated with 3-OHCBZ (10, 30, 100 or 300 µM) at 37±1ºC for up to 60 min in the presence of an NADPH-generating system and the presence or absence of either GSH (10 or 500 µM) or NAC (500 µM). Controls contained microsomes preincubated in the presence or absence of 3-OHCBZ (100 µM), but lacked NADPH. Preincubation mixtures were then diluted 10-fold with potassium phosphate buffer (50 mM, pH 7.4), MgCl 2 (3mM), EDTA (1 mM) and testosterone (250 mM). Reactions were initiated by the addition of NADPH-generating system.
Reactions were terminated with ice-cold methanol after 10-20 min. Protein was sedimented by centrifugation and an aliquot of the supernatant was analyzed by reverse phase HPLC via direct injection, as described by Usmani et al (2003) . CYP3A4/5 activity was measured as testosterone 6β-hydroxylase activity.
Irreversible binding of CBZ and 3-OHCBZ to microsomal proteins. ] and EDTA (1 mM) in a final incubation volume of 0.2 ml. After a 3 minpreincubation at 37°C, reactions were initiated by the addition of fresh NADPH (1.5 mM) (not added to controls). Freshly prepared GSH (1 or 4 mM) was added to some incubations to determine the level of reactive metabolite binding external to the P450 active site. After 30 min, the reaction was terminated with ice-cold methanol/5% H 2 SO 4 (10 volumes). Rat liver microsomes (10 mg protein) were added as a protein carrier, and the protein was precipitated on ice for 15 min. The protein precipitate was collected by sedimentation at 650g for 10 min in a Beckman GS-6R centrifuge, resuspended in ice-cold methanol/5% H 2 SO 4 (10 volumes) and resedimented. This step was repeated and followed by the addition of unlabelled CBZ or 3-OHCBZ solution in ethanol (20 mM stock; 20 µl) to the protein precipitate to reduce non-specifically bound radio-labeled compound. Following resuspension in ice-cold methanol/5% H 2 SO 4 (10 volumes) and resedimentation, the protein precipitate was sequentially "washed" free of adventitious substrates/metabolites by resuspension/resedimentation, once with acetone, three Incubations containing recombinant human P450 enzymes were performed as described above with the following exceptions: P450 concentrations were maintained at 0.5 µM, the concentration of [ to be included for optimal activity (Gillam et al., 1993) , hence incubations containing purified CYP3A4 in the absence of GSH were not performed.
HPLC/MS analysis of 3-OHCBZ biotransformation. 3-OHCBZ and its metabolites were resolved on a reversed-phase Phenomenex (Torrance, CA) Luna TM C-8 (2) column (4.6 mm x 25 cm, 5 µm particle size)
preceded by a Phenomenex C-8 guard column (4 mm x 3mm i.d., 5 µm particle size) using a Hewlett Packard HP1100 HPLC system equipped with a HP1100 de-gasser, binary pump, auto-sampler, column heater, diode array detector and mass spectral detector (Hewlett Packard Instruments, Santa Clara, CA).
The mobile phase consisted of 0.1% aqueous acetic acid (solvent A) and methanol (solvent B) and was ) between the rates of 2,3-diOHCBZ formation and the activities of cytochrome P450 enzymes were determined using least-squares regression analysis.
Significance was determined by Pearson's regression analysis using a two-tailed Student's t test (SPSS 11.0, SPSS Inc., Chicago, IL). A two-tailed, Student's t test (SPSS) was also used to determine Therefore, kinetic data were subsequently analyzed by non-linear regression without weighting (GraFit 5;
Erithacus Software Ltd, Surrey, UK) using a sigmoidal V max equation equivalent to the Hill equation
where S 50 is the substrate concentration showing a half-maximal velocity, n is a measure of cooperativity, and Vmax is the maximal velocity.
Contributions of individual P450 enzymes to the formation of 2,3-diOHCBZ in human liver microsomes were estimated by application of the Relative Activity Factor (RAF) approach (Venkatakrishnan et al., 2000) . RAFs were determined for specific CYPs by comparing the rate of an isoform-specific index reaction at saturating concentrations in human liver microsomes (V max ) to the rate of the same reaction catalyzed by recombinant enzymes under identical conditions. Thus, RAF isoform = V max for isoform-specific reaction in human liver microsomes V max for isoform-specific reaction in recombinant enzymes S-Mephenytoin 4'-hydroxylation and testosterone 6β-hydroxylation were used as the isoform-specific reactions for CYP2C19 and CYP3A4, respectively, in this study.
Predicted activities for each CYP isoform (V CYPx ) in human liver microsomes were estimated by multiplying the rate of the reaction catalyzed by cDNA-expressed enzymes (V rec-CYPx ) by the appropriate scaling factor, RAF. 
Predicted contributions of each recombinant P450 to the clearance of 3-OHCBZ by 2-hydoxylation were calculated using experimentally derived kinetic parameters for cDNA-expressed CYPs and the following equation:
where CYPx is an individual recombinant enzyme, Cl CYPx is the clearance (V max /K m ) of the given isoform, and sum Cl CYPn is the sum of the predicted clearances for each of the recombinant forms contributing to the given reaction.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Identification of catechol product, 2,3-diOHCBZ. In the absence of an authentic standard for 2,3-diOHCBZ, its identification in reaction mixtures was inferred from the results of experiments conducted with 2-OHCBZ and 3-OHCBZ as substrates. Human liver microsomes converted 3-OHCBZ to at least five primary metabolites, two of which had mass and fragmentation patterns consistent with those of a dihydroxycarbamazepine metabolite by HPLC-MS. Utilizing the same HPLC/MS conditions, three metabolites with mass spectral properties consistent with those of a dihydroxycarbamazepine metabolite were detected in NADPH-fortified human liver microsomal incubations containing 2-OHCBZ as the substrate, but only one of these metabolites had the same retention time as one of the dihydroxycarbamazepine metabolites formed from 3-OHCBZ ( Fig. 2 ). Only one dihydroxycarbamazepine metabolite, namely 2,3-diOHCBZ, has been identified as being common to the CBZ metabolic pathways that proceed through 2-OHCBZ and 3-OHCBZ (Lertratanangkoon and Horning, 1982) . Therefore, we conclude that the dihydoxycarbamazepine metabolite observed in our experiments is the catechol, 2,3-diOHCBZ, although this conclusion remains to be confirmed empirically. No metabolite formation was observed from 3-OHCBZ in the absence of NADPH or human liver microsomes.
Although 2,3-diOHCBZ can be produced from either 2-OHCBZ or 3-OHCBZ, it appears that the metabolic pathway from CBZ to 3-OHCBZ to 2,3-diOHCBZ is responsible for the majority of 2,3-diOHCBZ produced in human liver microsomes. The basis for this statement is derived from two observations. First, the rate of 2,3-diOHCBZ formation in human liver microsomes was at least five times greater when 3-OHCBZ (10 µ M) served as substrate than when 2-OHCBZ (10 µ M) was the substrate (data not shown). Second, the ratio of 3-OHCBZ to 2-OHCBZ formed from CBZ (100 µ M) varied from 26:1 to 80:1 in a subset of the panel of human liver microsomes used in this study (Pearce et al., 2002) . This suggests that conversion of CBZ to 2,3-diOHCBZ is at least two orders of magnitude greater when it proceeds through 3-OHCBZ rather than through 2-OHCBZ. Hence a principal aim of this study was to characterize the P450 enzymes responsible for the formation of 2,3-diOHCBZ from 3-OHCBZ, but not from 2-OHCBZ.
Formation of 2,3-diOHCBZ by cDNA-expressed human P450 enzymes. Microsomes prepared from bacculovirus-infected insect cells expressing vector alone (control) or one of fourteen cDNA-expressed
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3 ). CYP2C19 and CYP3A4 catalyzed the highest rates of 2,3-diOHCBZ formation, forming the metabolite at rates (1.62 ± 0.04 and 1.08 ± 0.03 pmol/pmol P450/min, respectively) that were at least six fold higher than those of the next most active enzyme, namely,
CYP1A1.
Concentration-dependence of 2,3-diOHCBZ formation by cDNA-expressed CYPs and human liver microsomes. Based on the experimental results described above, kinetic studies were performed with recombinant CYP2C19 and CYP3A4, and with human liver microsomes. Conversion of 3-OHCBZ (5-500 µM) to 2,3-diOHCBZ did not appear to conform to a typical Michaelis-Menten kinetic profile in any of the three systems; the kinetics exhibited a slight sigmoidicity, characterized by hooked Eadie-Hofstee plots (Fig. 4) . The solubility of 3-OHCBZ (limited to ~50 mM in methanol) and consideration for solvent concentration (≤1%) in incubation mixtures precluded substrate concentrations exceeding 500 µ M, a concentration below that necessary to reach enzyme saturation for human liver microsomes and CYP3A4, but one that did approach the concentration necessary to saturate CYP2C19. Kinetic parameters for 2,3-diOHCBZ formation were estimated using the Hill equation, and are presented in Table 1 . The apparent S 50 value for the formation of 2,3-diOHCBZ by recombinant CYP3A4 (~203 and TAO markedly inhibited the formation of 2,3-diOHCBZ (~80%) in pooled human liver microsomes (Fig. 6) . The other chemicals examined caused little or no inhibition of 2,3-diOHCBZ formation (<15%), although α-naphthoflavone, an inhibitor of CYP1A2 with the ability to stimulate CYP3A activity (Shou et al., 1994) , caused a 2-to 3-fold increase in the formation of 2,3-diOHCBZ. Omeprazole and quinidine, which are substrates for CYP3A4 as well as inhibitors of CYP2C19 and CYP2D6, respectively, caused slight increases (< 1.5-fold) in the rate of 3-OHCBZ conversion to 2,3-diOHCBZ.
Under conditions that virtually eliminate CYP3A activity in human liver microsomes, i.e., a concentration of 100 µM TAO and a pre-incubation period of 20 min prior to addition of substrate, TAO markedly inhibited, but did not eliminate formation of 2,3-diOHCBZ. This finding suggested that the residual formation of 2,3-diOHCBZ (~20%) might be catalyzed by CYP2B6, CYP2C19 or other additional P450
enzymes. To investigate this observation further, the panel of 14 human liver microsomal preparations was incubated with 3-OHCBZ (100 µM) following a 20-min preincubation with or without TAO (100 µM),
and the results are shown in Fig. 5 . In the presence of TAO, the residual rate of 2,3-diOHCBZ formation correlated significantly with the activities of CYP2C19 (r 2 = 0.893, P < 0.001), CYP1A2 (r 2 = 0.390, P = 0.017) and CYP4A (r 2 = 0.316, P = 0.036), but not with the activities of any other P450 enzymes (Appendix 1). The correlation between 2,3-diOHCBZ formation and the latter two P450 activities may be fortuitous since CYP2C19 activity was significantly correlated with CYP1A2 (r 2 = 0.410, P = 0.014) and CYP4A (r 2 = 0.350, P = 0.026) activities in the panel of human liver microsomes.
Contribution of CYP2C19 and CYP3A4 to 2,3-diOHCBZ formation in human liver microsomes.
Cumulatively, the data from experiments with recombinant P450s, correlation studies and inhibition studies consistently identified CYP2C19 and CYP3A4 as the primary catalysts of 2,3-diOHCBZ formation from 3-OHCBZ. Therefore, the relative contributions of these two P450s to the 2-hydroxylation of 3-OHCBZ (10 µ M) were investigated in the panel of 14 human liver microsomal preparations using the RAF approach, as described in Materials and Methods. Using this approach, calculated rates of 2,3-diOHCBZ formation by CYP2C19 and CYP3A4 in human liver microsomes were comparable to rates determined empirically (r 2 = 0.865). In most cases, calculated rates reflected the rates observed experimentally in the human liver microsomal samples (Table 2 ). However in subjects H064 and H103, for example, the calculated rate of 2,3-diOHCBZ formation was markedly different from that determined experimentally (up to 2.4-fold different). Thus, it is possible that the estimated contributions of CYP2C19 and CYP3A4 to 2,3-diOHCBZ formation presented in Table 2 may not represent the true contribution of these enzymes to formation of 2,3-diOHCBZ in all individuals. One explanation is that, enzymes in addition to CYP2C19
and CYP3A4 contribute to 2,3-diOHCBZ. Nevertheless, the derived kinetic parameters for the recombinant enzymes provide an adequate estimate of each isoform's contribution to the overall intrinsic clearance of 2,3-diOHCBZ formation. The estimated per cent contribution of CYP2C19 to the intrinsic clearance of 2,3-diOHCBZ formation ranged from 0.8 to 60.1%, whereas the contribution by CYP3A4
accounted for most of the remaining activity (39.9 to 99.1%). The per cent contribution of each of the enzymes to 2,3-diOHCBZ formation appears to be highly variable among individuals and dependent on the P450 expression profile of each individual. In most of the microsomal preparations, CYP3A4 appears to be the dominant enzyme catalyzing 2,3-diOHCBZ formation at low substrate concentrations. However, in human liver microsomes prepared from donor H056, CYP2C19 appears to be the principal catalyst of this reaction.. 
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Preincubation-dependent inhibition of CYP3A4/5. In preliminary experiments designed to optimize conditions for 2,3-diOHCBZ formation by recombinant CYP2C19 and CYP3A4, we observed that formation of 2,3-diOHCBZ was linear with time (up to 60 min) with CYP2C19, whereas with CYP3A4, the rate of metabolite formation was proportional with time only up to 15 min, with a decline in the rate thereafter (Fig. 7) . As these results suggested that CYP3A4, but not CYP2C19, may be inactivated by a metabolite generated from 3-OHCBZ, studies were conducted to examine preincubation time-dependent inhibition of CYP3A4 by 3-OHCBZ (10, 30, 100 or 300 µM) in pooled human liver microsomes and in cDNA-expressed CYP3A4. In order to minimize any competitive enzyme inhibition that might be present, human liver microsomes were preincubated with 3-OHCBZ in the presence of NADPH-generating system for 0-60 min, followed by a 10-fold dilution of the incubation volume prior to the determination of CYP3A activity, as measured by testosterone 6β-hydroxylase activity. Using this approach, preincubation of 3-OHCBZ with human liver microsomes or cDNA-expressed CYP3A4 led to decreased CYP3A4 activity, which was both preincubation time-and concentration-dependent (Figs. 8 and 9 ). Loss of CYP3A activity due to 3-OHCBZ preincubation was also determined to be NADPH-dependent. Kinetic constants of inactivation were determined from the fit of the rate constants of inactivation (slope of enzyme of log- ranged from 10.5 to 55.7% among the microsomal samples (Fig. 10) , and the rate of 3-OHCBZ-mediated inactivation of CYP3A activity was correlated significantly with the rate of 2,3-diOHCBZ formation (r 2 = 0.880, P < 0.001). 
Irreversible
Discussion
As is the case with most drug-induced hypersensitivity reactions, the mechanism underlying the hypersensitivity responses to aromatic anticonvulsants is not well understood. Drug molecules (<1000 Da) are generally considered to be too small to be inherently immunogenic, hence it has been proposed that most drug-induced hypersensitivity reactions require the bioactivation of a drug into one or more reactive metabolites capable of binding covalently with cellular proteins (Park et al., 1987) . These modified proteins may subsequently function as neo-antigens capable of initiating an immune response.
However, the process by which most of these drug-modified macromolecules elicit an immune response is unclear.
Reactive metabolites formed from several drugs have been demonstrated to inactivate cytochrome P450s
by binding to the protein in or near the active site, or alternatively, by binding to the heme moiety. This mechanism-based inhibition is characterized by NADPH-, time-and substrate concentration-dependent inactivation (Guengerich, 2001) . In most instances, these damaged proteins do not elicit an immune response, but simply undergo intracellular degradation. However, under the appropriate circumstances, the formation of P450 adducts with certain drugs in susceptible individuals results in the initiation of an immune response that targets either the P450-adduct or the native P450 enzyme itself.
Antibodies which recognize drug-adducted P450s (trifluoroacetyl-CYP2E1 and tienilic acid-CYP2C9) have been detected in the sera of patients with halothane-induced (Eliasson and Kenna, 1996) and tienilic acid-induced (Lecoeur et al., 1996) hepatitis, respectively. However, most often drug-induced serum anti-P450 antibodies appear to recognize native protein sequences, such as that seen with dihydralazine (CYP1A2) (Bourdi et al., 1994) , disulfiram (CYP1A2) (Eliasson et al., 1998) , isoflurane (CYP2A6) (Martin et al., 2001) , the immunosuppressants, cyclosporine and FK506 (CYP3A4, CYP2E1, CYP1A2 and CYP2C9) (Lytton et al., 2002) , ethanol (CYP2E1 and CYP2C9) (Lytton et al., 1999) , the anticonvulsants, phenytoin and CBZ (CYP3A and CYP2C forms) (Riley et al., 1993; Leeder et al., 1996) as well as halothane (CYP2E1) (Eliasson and Kenna, 1996) and tienilic acid (CYP2C9) (Lecoeur et al., 1996) , rather than the drug-derived hapten.
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Circulating anti-P450 antibodies present in patients treated with halothane, tienilic acid or dihydralazine have been shown to be directed at the P450s responsible for the bioactivation of these compounds.
Moreover, the enzymes responsible for catalyzing the formation of protein reactive metabolites all suffered inactivation that was NADPH-, time and substrate concentration dependent. These data support the hypothesis that there is a group of drugs which are associated with idiosyncratic toxicity that are converted to metabolites that inactivate the enzyme responsible for their bioactivation and subsequently become targets of circulating antibodies after initiation of an immune response. The results of the present study indicate that the CBZ metabolite, 3-OHCBZ, can be converted into a reactive species that not only forms a CYP3A4 covalent adduct, but is also capable of inactivating CYP3A4 in a mechanism-based manner.
Previous in vitro studies have demonstrated the bioactivation of CBZ by the formation of both cytotoxic be converted into a reactive species that not only forms a CYP3A4 covalent adduct, but it is also capable of inactivating CYP3A4 in a mechanism-based manner. When combined with the knowledge that sera from CBZ-hypersensitive patients often contain antibodies that recognize CYP3A proteins (Leeder et al., 1996) , this suggests that CBZ may belong with the aforementioned group of drugs that initiate idiosyncratic hypersensitivity following the inactivation and covalent binding of reactive metabolites with the P450 enzyme mediating their formation.
Unfortunately, it was not possible to ascertain the identity of the metabolite(s) responsible for CYP3A4 inactivation and/or adduct formation from the studies reported here. Initially, we speculated that conversion of 3-OHCBZ to the catechol, 2,3-diOHCBZ, followed by a subsequent oxidation step could (267) consistent with that of CBZ-quinone (data not shown) were observed in incubations containing relatively high concentrations of 3-OHCBZ (≥100 µM), the identity of this metabolite has not been confirmed nor is there direct evidence to determine whether CBZ-quinone was involved in the CYP3A4 inactivation and/or adduct formation observed in the studies reported here. It is possible that CYP3A4 converts 3-OHCBZ into metabolites other than (or in addition to) CBZ-quinone that are sufficiently reactive to inactivate CYP3A4 directly. Evidence is presented in the accompanying paper for myeloperoxidase-and H 2 O 2 -mediated formation of one or more free radical intermediates from 3-OHCBZ (depicted in Fig. 1 ). Similar reactive species could be formed by CYP3A4, since it is known that P450s are capable of generating free radical species via a single electron oxidation followed by release of the intermediate, resulting in an interruption of the typical P450 two-electron oxidation cycle (Guengerich, 2001) . Certainly any uncoupling of the CYP3A4 cycle, would generate reactive oxygen species, which could damage the CYP3A4 active site either directly or indirectly, possibly through accelerated oxidation of 2,3-diOHCBZ to CBZ-quinone, as has been proposed previously for a catechol metabolite of tamoxifen (Notley et al., 2002) . Another possibility is that CYP3A4 could catalyze the formation of a reactive quinone methide from 3-OHCBZ, in a manner analogous to that of CBZ-iminoquinone formation from 2-OHCBZ.
Significant cross-sensitivity between CBZ and phenytoin has been observed in patients experiencing hypersensitivity reactions to aromatic anticonvulsants, which suggests that the mechanisms mediating adverse reactions to these two drugs may be similar, including the formation of similar metabolites. The biotransformation/bioactivation pathway converting CBZ to 2,3-diOHCBZ demonstrates a striking similarity to the bioactivation pathway described for phenytoin. Like CBZ, phenytoin can be converted to a catechol, 3',4'-dihydroxyphenytoin, which has been demonstrated to form protein reactive intermediates via the subsequent oxidation of the catechol to reactive semiquinone and quinone species (Munns et al., 1997) . Furthermore, the P450 enzymes responsible for catalyzing the formation of the catechol, largely CYP2C18, CYP2C19 and CYP3A4, have also been shown to be the major targets of covalent adduct formation (Cuttle et al., 2000; Komatsu et al., 2000; Kinobe et al., 2005) . Interestingly, phenytoin has also been reported to form a reactive free radical intermediate (Parman et al., 1998 are CYP3A4 and CYP2C19, the same enzymes largely responsible for catalyzing 3',4'-dihydroxyphenytoin formation and that are major targets of covalent adduct formation with phenytoin-derived reactive species. Although CYP2C19 appears to be predominantly expressed in liver and duodenum (Klose et al., 1999) , the tissue distribution of CYP3A4 includes liver and a number of extrahepatic tissues, such as kidney, skin, intestine, and blood (Lamba et al., 2002) , which parallels the sites of involvement observed in anticonvulsant hypersensitivity. When this information is combined with the bioactivation data for phenytoin and 3-OHCBZ and with the previous epitope mapping studies of patients' serum antibodies (Leeder et al., 1996) , it becomes enticing to speculate that an anticonvulsant adduct of CYP3A4 (or an altered degradation product of such an adduct) may function as at least one of the antigens eliciting a hypersensitivity response to aromatic anticonvulsants. Involvement of a common target and a similar mechanism of bioactivation for phenytoin and CBZ could potentially explain, at least in part, the ability of these compounds to cross-react in the development of hypersensitivity reactions. Ultimately, investigation of the cellular consequences of reactive metabolite/covalent adduct formation may lead to the elucidation of the mechanism by which drug bioactivation and immune responses interact and contribute to the pathogenesis of idiosyncratic reactions to aromatic anticonvulsants. The NADPH-regenerating system consisting of isocitrate and isocitrate dehydrogenase (ICDH) was added to incubations along with NADPH (1.5 mM) in order to recycle any NADP + generated in the reaction back into NADPH. The ICDH conversion of isocitrate and NADP + to oxalosuccinate + NADPH does not require Mn +2 (or Mg   +2 ) ions (Moyle, J, Biochem J, 63:552, 1956 ). However, the subsequent coupled reaction, i.e., the formation of α-ketoglutarate from oxalosuccinate does, and Mn +2 is found to accelerate NADPH formation by stimulating the forward reaction, but is not an obligatory cofactor (Moyle, 1956 ). The Sigma ICDH enzyme used in the experiments described in this manuscript was supplied with Mn +2 ions (manganous sulfate), and the 0.1 M phosphate buffer used in the reaction also contained traces of Mn +2 and Mg +2 ions. For these combined reasons additional Mg +2 was not included, as is necessary if NADPH is to be generated totally from NADP + .
This article has not been copyedited and formatted. The final version may differ from this version. Incubations containing human liver micrsomes were terminated after 30 min, whereas incubations containing CYP3A4 and CYP2C19 were terminated after 10 and 15 min, respectively. Following precipitation of microsomal protein, an aliquot (75 µl) of the supernatant was analyzed by HPLC/MS via direct injection, respectively, as described under Materials and
Methods.
This article has not been copyedited and formatted. The final version may differ from this version. in incubations containing liver microsomes from Dex-treated mice or purified recombinant CYP3A4 functionally reconstituted, respectively) and are denoted with a (+); whereas incubations conducted in the absence of GSH are denoted with a (-). Functional reconstitution of purified CYP3A4 requires that GSH be included for optimal activity (Gillam et al, 1993) , hence incubations containing purified CYP3A4 in the absence of GSH were not performed.
After 30 min, reactions were terminated with ice-cold methanol/5% H 2 SO 4 , microsomal proteins precipitated, sedimented and sequentially "washed" to reduce non-specifically bound radiolabelled substrates or metabolites, as described in Materials and Methods. Each of the rates of irreversible binding determined in incubations performed in the presence of NADPH were found to be significantly different from the corresponding rates determined in incubations performed in the absence of NADPH (controls) as detemined using a two-tailed, paired Estimated per cent contribution of each isoform. Values in parentheses are the estimated per cent contribution of CYP2C19 and CYP3A4 calculated under the assumption that formation of 2,3-diOHCBZ is principally catalyzed by these two isoforms at a concentration of 10 µM 3-OHCBZ. 
